Amarin (AMRN 0.79%) investors, it's almost that time again. The FDA's Orange Book should be updated later this week and it may contain news regarding Vascepa. Whether the NCE decision is finally put to rest or if yet another delay is in the cards is anyone's guess. However, there are plenty of other aspects to Amarin's business that investors all need to pay attention to. In this video, health-care analyst Max Macaluso runs through the main issues investors need to watch in the coming weeks.
The (potential) NCE decision is upon us once again.
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo